A study from Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK shows that MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. This study was published in the April 14, 2014 Cancer Cell by Prof. Dr Valeri N and others.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Treating human cancer with a Diabetic pill: Acarbose, an anti-diabetic drug used to treat non-insulin-dependent Diabetes Mellitus, inhibits the expression of oncogenic MiRNA-135b via up regulation of its target gene. MiRNA-135b has been shown to promote colon cancer by (1) acting as a downstream effector of oncogenic pathways; and (2) inhibiting the expression of a number of tumor suppressor proteins. Based on this, we propose here a therapeutic strategy as to how one can cure colon cancers over-expressing miRNA-135. Taken together, this study suggests that pharmacological formulations encompassing “Acarbose or its analogues” can be used in the treatment of colon cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Treating human cancer with a Diabetic pill: Acarbose, an anti-diabetic drug used to treat non-insulin-dependent Diabetes Mellitus, inhibits the expression of oncogenic MiRNA-135b via up regulation of its target gene, 20/April/2014, 6.43 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
